These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28092994)

  • 1. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.
    Cowan RA; O'Cearbhaill RE; Zivanovic O; Chi DS
    Int J Hyperthermia; 2017 Aug; 33(5):548-553. PubMed ID: 28092994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
    Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
    Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
    Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
    J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Koole SN; van Driel WJ; Sonke GS
    Cancer; 2019 Dec; 125 Suppl 24():4587-4593. PubMed ID: 31967678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
    Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
    Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
    de Bree E; Helm CW
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):895-911. PubMed ID: 22845405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Vergote I; Harter P; Chiva L
    Cancer; 2019 Dec; 125 Suppl 24():4594-4597. PubMed ID: 31967685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
    Wang JY; Gross M; Urban RR; Jorge S
    Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
    ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Micha JP; Bohart R; Goldstein BH
    Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():101-105. PubMed ID: 31778904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.